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Anti-tissue factor pathway inhibitor activity in
subjects with antiphospholipid syndrome is
associated with increased thrombin generation 
The antiphospholipid syndrome (aPS) isa heterogeneous disorder characterizedby circulating antiphospholipid anti-
bodies (aPL ), with venous or arterial throm-
bosis, recurrent miscarriages and thrombo-
cytopenia.1 APL target phospholipid bound
proteins, including β-2-glycoprotein-I
(β2GPI) and prothrombin, with varying
specificity.2 It has been proposed that aPL
contribute directly to the clinical manifes-
tations of aPS,2 though no single mecha-
nism has been clearly identified. On the
other hand, the heterogeneity of clinical
manifestations of aPS probably reflects
multiple contributing factors that lead to
the development of hypercoagulability.
These include, but are not limited to, inter-
ference with platelet function,3,4 inhibition
of the protein C anticoagulant system5,6 and
inhibition of fibrinolysis.7
Changes to the tissue factor (TF) pathway
of coagulation have more recently been
implicated in the development of hyperco-
agulability in aPS.8 Indeed, inhibitory activ-
ity (in IgG fractions) against tissue factor
pathway inhibitor (TFPI)9 and autoantibodies
(in plasma) to TFPI10,11 have been identified
in aPS subjects. Whether these are actually
the same entity remains to be elucidated,
but it would seem feasible that anti-TFPI
activity is due to the contribution of anti-
TFPI antibodies and possibly other cross-
reacting aPL. An impaired ability of TFPI to
regulate the TF pathway, for example by an
anti-TFPI antibody or another interfering
factor, may contribute significantly to the
development of a prothrombotic state. The
aim of this study was, therefore, to investi-
gate how in vitro TF-induced thrombin gen-
eration was affected by IgG fractions from
aPS subjects containing anti-TFPI activity.
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Background and Objectives. Immunoglobulin G (IgG) fractions from subjects with
antiphospholipid syndrome (aPS) have previously been demonstrated to have inhibitory
activity against tissue factor pathway inhibitor (TFPI).  This may contribute to the devel-
opment of a prothrombotic state by impaired regulation of the tissue factor (TF) path-
way.  This study investigated the effect that IgG fractions from aPS subjects containing
anti-TFPI activity have on in vitro TF-induced thrombin generation.
Design and Methods. TFPI and anti-TFPI activities were determined in normal controls
(n=29) and aPS subjects (n=57). TFPI activity was determined using an amidolytic assay
based on the generation of factor Xa. Anti-TFPI activity was determined after incubating
IgG isolated from a control or subject plasma with pooled normal plasma, using the TFPI
activity assay.  The influence of IgG fractions from controls (n=10) and subjects (n=23)
on TF-induced in vitro thrombin generation was determined using a chromogenic assay
of thrombin activity.
Results. TFPI activity in controls (1.13±0.25 U/mL) was significantly lower than in sub-
jects (1.30±0.42 U/mL) (p < 0.05).  Anti-TFPI activity was significantly higher in subjects
than controls (p = 0.0001). TF-induced thrombin generation was positively associated
with anti-TFPI activity (ρ = 0.356; p > 0.05), with increased levels of each demonstrat-
ed in 5 subjects.
Interpretations and Conclusions. Anti-TFPI activity was confirmed in 65% of aPS sub-
jects. IgG fractions demonstrated a variable ability to interfere with TFPI function and TF-
induced thrombin generation. Cross-reacting antiphospholipid antibodies and/or other
entities may interfere with TFPI function, resulting in a net increase in thrombin gener-
ation and an increased thrombotic risk.
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Design and Methods
Ethics
The study was approved by the Human Research
Ethics Committee of Curtin University (Approval Num-
ber: HR 238/2001) and the Ethics Committee of Royal
Perth Hospital (Reference: EC 2002/013).
Patients and controls
Venous blood was collected from 29 normal con-
trols (M=18; F=11; mean age: 24.6±8.6 years) and 57
aPS subjects (M=28; F=29; mean age: 50.2±20.2
years). Subjects presented with a history of aPS-relat-
ed clinical features or demonstrated aPS laboratory
markers. Nine parts whole blood was collected into 1
part 0.109 mol/L tri-sodium citrate. Plasma was pre-
pared by centrifugation at 1,800 g for 15 minutes at
room temperature. The plasma was separated and cen-
trifuged again to ensure that platelet-poor plasma was
collected. Samples were aliquoted and stored at –70˚C
until required.
Pooled normal plasma was prepared from 20 normal
male donors. Equal volumes of plasma from each
donor were pooled, mixed, aliquoted and stored at
–70˚C until required. Pooled normal plasma was des-
ignated to contain 1 U/mL TFPI activity.
TFPI activity assay
TFPI activity was measured using an amidolytic assay
based on a previously described method.12 Prior to the
assay, test or standard plasmas were heated at 56˚C for
15 minutes, placed on melting ice for 2 minutes then
centrifuged for 15 minutes at 1,800 g. Diluted test or
standard plasma (25 µL) was incubated with 100 µL of
a reaction mixture, which contained equal amounts
of recombinant TF (Innovin®, Dade Behring, Marburg,
Germany) (diluted 1/40 in TFPI assay buffer contain-
ing 0.15 mol/L NaCl, 0.05 mol/L Tris, 0.01 mol/L trisodi-
um citrate, 0.1% normal serum albumin and 0.02%
polybrene, pH 8.0), 0.03 U/mL FVII (Enzyme Research
Laboratories, Southbend, USA), 0.025 U/mL FX (Sigma
Chemical Company, St Louis, USA), and 0.05 mol/L
CaCl2, in U-bottomed microtiter plates (Australian
Biosearch, Perth, Australia). After incubation for 20
minutes at 37˚C, 50 µL of substrate mixture, contain-
ing 0.4 U/mL FX and 2.7 mmol/L synthetic peptide sub-
strate (S-2222; Chromogenix, Milan, Italy), were added
and incubated at 37˚C for a further 30 minutes. The
reaction was stopped by the addition of 50 µL of 50%
acetic acid and the absorbance read at 405 nm using
a Multiskan Acent microtiter plate spectrophotometer.
The assay was standardized using pooled normal plas-
ma from 20 healthy male donors.
IgG isolation
IgG fractions were isolated from plasma by affinity
purification using a protein G column according to the
manufacturer’s instructions (Amersham Pharmacia
Biotech, Uppsala, Sweden). Samples were diluted 1 in
5 in 0.02 mol/L phosphate-buffered saline (PBS) pH 7.4
and pushed slowly through the column using an
attached syringe. After washing the column with 10 mL
of 0.02 mol/L PBS pH 7.4, IgG was eluted with 5 mL of
0.1 mol/L glycine-HCl pH 2.8 and collected as 1 mL
aliquots into 100 µL of 1.0 mol/L tris-HCl pH 9.0. The
absorbance of each aliquot was measured at 280 nm
and the two aliquots with the highest absorbance and
0.5 mL of the third highest aliquot were pooled. Buffer
exchange was performed using PD 10 desalting columns
(Amersham Pharmacia Biotech, Uppsala, Sweden),
equilibrated with 15mL of TFPI assay buffer pH 8.0 or
0.02 mol/L PBS pH 7.4. Isolated IgG (2.5 mL) was passed
through the desalting column and eluted with 3.5 mL
of the appropriate buffer. The concentration of IgG was
determined by measuring the absorbance of the pooled
aliquots with a 1 cm light path and an extinction coef-
ficient of E1%, 1cm = 13.6, and stored at –70˚C.
Preparation of pooled normal IgG
Following isolation (as described above) from 22 nor-
mal controls, IgG fractions were adjusted to a concen-
tration of 500 µg/mL with PBS pH 7.4 and an equal vol-
ume of each fraction pooled, aliquoted and stored at
–70˚C until required.
Determination of anti-TFPI activity
IgG fractions (25 µg/mL) were mixed with pooled nor-
mal plasma for 30 minutes at 37˚C. The IgG and pooled
normal plasma mixtures were then re-assayed for TFPI
activity. Anti-TFPI activity was designated as the differ-
ence between TFPI activity in the IgG-pooled normal
plasma mixture and the control (buffer/pooled normal
plasma; 1 U/mL). 
Assay of thrombin generation
A chromogenic assay based on the method of Sheng
et al.13 was used to determine the effect of IgG fractions
from controls and aPS subjects on TF-induced in vitro
thrombin generation. Plasma was initially defibrinated
by heating at 53˚C for 20 minutes, incubation on melt-
ing ice for 2 minutes and centrifugation at 3,000 g for
10 minutes. Thromboplastin (25 µL, diluted 1/10 in 0.9%
NaCl) and 50 µL of defibrinated plasma (diluted 1/2 in
0.02 mol/L PBS pH 7.4 or 25 µg/mL IgG/antibody) were
incubated for 10 minutes at 37˚C. Chromozyme TF sub-
strate (Roche Diagnostics, Sydney, Australia) was dilut-
ed in 0.9% NaCl to a concentration of 0.95 mmol/L and
50 µL added to each well. Following addition of 30
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mmol/L CaCl2 (50 µL), the absorbance was measured at
405 nm every two minutes until the peak absorbance
was obtained. Each sample was measured for back-
ground absorbance by substituting TF with 25 µL of
0.9% NaCl. At each time point the absorbance of the
background wells was subtracted from the absorbance
of the corresponding test wells. This resulted in the final
corrected absorbance for each sample assessed. Throm-
bin generation (%) was determined by dividing the
absorbance at 1/2max of the test mixture by the
absorbance at 1/2max of a blank (containing 0.9% NaCl
instead of test or control IgG).
A sheep anti-rabbit TFPI antibody (a gift from Dr P.
Tipping, Monash University, Australia) and pooled IgG
from normal controls were used as controls.
Statistics
Results were analyzed using StatViewSE+Graphics for
MacIntosh (Abacus Concepts, Berkeley, USA). Results are
expressed as mean ± standard deviation (SD) for TFPI
activity or median (inter-quartile range) for other data
sets. Between group differences were assessed using Stu-
dent’s t-test for normally distributed data (TFPI activity)
or the Wilcoxon signed rank test for non-parametric
data. Correlations between sets of data was determined
using Spearman’s correlation co-efficient. p values < 0.05
were considered to be statistically significant.
Results
TFPI activity
TFPI activity (mean±SD) in controls (1.13±0.25 U/mL)
was significantly lower than in aPS subjects (1.30±0.42
U/mL) (p < 0.05) (Figure 1). Two aPS subjects had TFPI
activity below the lower 95% confidence interval (< 0.63
U/mL) of the normal range (0.57 and 0.53 U/mL, respec-
tively). Seven aPS subjects had TFPI activity above the
upper 95% confidence interval (> 1.63 U/mL) of the
derived normal range.
Anti-TFPI activity
Anti-TFPI activity was detected in 3/29 (10%) controls
(0.01, 0.02 and 0.02 U/mL) and in 37/57 (65%) aPS sub-
jects [median = 0.03 (0.02 – 0.06 U/mL)] (Figure 2). Anti-
TFPI activity was significantly greater in aPS subjects
than in controls (p = 0.0001). There was no correlation
between TFPI activity and anti-TFPI activity in either
control or subject cohorts (p > 0.05).
TF-induced thrombin generation
The standard curve for the detection of in vitro TF-
induced thrombin was sigmoidal in shape (Figure 3), as
previously demonstrated.13 A sheep anti-rabbit TFPI anti-
body induced a concentration-dependent increase in
thrombin generation (Figure 4). Pooled IgG from normal
donors demonstrated no effect on thrombin generation
(Figure 4). The effect on TF-induced thrombin generation
by IgG fractions from 10 controls and 23 aPS subjects
was variable [100.5% (97.0 – 102.0%) vs 98.0% (89.5 –
105.5%)] (p > 0.05) (Figure 5). The effect of IgG fractions
from 23 of 57 aPS subjects tested on thrombin genera-
tion was positively correlated (ρ = 0.356) with anti-TFPI
activity (Figure 6), but this was not statistically signifi-
cant (p = 0.09). There was no correlation between the
effect of IgG on in vitro TF-induced thrombin generation
and TFPI activity in either control (p > 0.05) or subject
cohorts (p > 0.05).
987
Anti-TFPI activity and thrombin generation in aPS.
Figure 1. TFPI activity in normal controls and aPS sub-
jects. TFPI activity was significantly higher in aPS sub-
jects than in controls (p < 0.05) as measured by an ami-
dolytic activity assay.
Figure 2. Anti-TFPI activity in controls and aPS subjects.
Anti-TFPI activity was significantly higher in aPS subjects
than in controls (p = 0.0001) as measured by mixing IgG (25
µg/mL) from controls or aPS subjects with pooled normal
plasma and measuring by the TFPI amidolytic activity assay.  
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Discussion
Venous or arterial thrombosis is a frequent clinical
manifestation of aPS, though causal mechanisms remain
to be elucidated. It is probable that the development of
a hypercoagulable state is a consequence of multiple
significant abnormalities and/or imbalances of hemo-
static mechanisms, including the TF pathway. TFPI activ-
ity levels were initially demonstrated to be higher in aPS
subjects than in controls. Though variable levels of TFPI
activity (and antigen) have been reported in aPS sub-
jects14-17 recent experimental evidence supports up-reg-
ulation of the TF pathway as an important factor in the
development of hypercoagulability in aPS.8,9,11,18 Indeed,
increased TFPI activity in the plasma of aPS subjects
probably represents increased endothelial cell secretion
of TFPI. This may be a protective mechanism in response
to the direct influence of aPL, which have been demon-
strated to induce an increase in TF-like activity in mono-
cytes and endothelial cells.18-19
The presence of anti-TFPI activity was confirmed in
the cohort of aPS subjects used in this study. Interest-
ingly, anti-TFPI activity was demonstrated in a greater
proportion of subjects compared to an earlier study (65%
vs 15%).9 It is unclear why there is a large discrepancy
between these results, as the methods to measure anti-
TFPI activity were essentially the same. A relatively small
sample size in each study, or the use of fresh pooled nor-
Figure 3. TF-induced thrombin generation assay: stan-
dard curve. Thrombin generation of pooled normal plas-
ma as detected by a chromogenic substrate measured
over time.
Figure 4. TF-induced thrombin generation assay: controls.
Sheep anti-rabbit TFPI antibodies (crosses) inhibit TFPI
and therefore induce a concentration-dependent increase
in thrombin generation. Pooled normal IgG (circles) have
no effect on thrombin generation.
Figure 5. Effect of IgG fractions from controls and aPS
subjects on TF-induced thrombin generation.  IgG from
controls (crosses) have a narrow influence on thrombin
generation. IgG from aPS subjects (circles) have a wide
influence on thrombin generation.
Figure 6. Scatterplot of anti-TFPI activity vs TF-induced
thrombin generation using IgG from aPS subjects (ρ =
0.356).
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mal plasma instead of lyophilized reference plasma (not
calibrated for TFPI) to detect anti-TFPI activity, may have
contributed to the discrepant results.
The range of anti-TFPI activity in aPS subjects was
0.01 - 0.10 U/mL, reflecting variability in the strength of
the interference. Three (10%) of 29 normal controls also
demonstrated anti-TFPI activity, although levels (0.01 –
0.02 U/mL) were lower than those detected in the major-
ity of aPS subjects. This was not an unexpected obser-
vation as laboratory markers of aPS, lupus anticoagu-
lants (LA) and anticardiolipin antibodies (aCL), have been
reported in the plasma of normal individuals.20-23 Anti-
TFPI autoantibodies have also been reported in a small
percentage of normal individuals.11
The primary aim of this study was to investigate the
influence of IgG fractions from aPS subjects on in vitro
TF-induced thrombin generation. The assay, based on a
previously published method,13 measures the effect of
antibody, IgG or plasma in a chromogenic substrate assay
of thrombin generation. It detects both LA and β2GPI
dependent aCL antibodies and probably has greater
specificity for aPS than currently available diagnostic
tests.13 It was hypothesized in the present study that IgG
fractions obtained from the plasma of aPS subjects
which contained anti-TFPI activity would increase in vit-
ro TF-induced thrombin generation. Physiological con-
centrations of TFPI have been demonstrated to reduce
the rate of thrombin generation,24 thus it was predicted
that inhibition of TFPI activity would increase the rate of
thrombin generation.
It was initially demonstrated in control experiments
that a sheep anti-rabbit TFPI antibody increased in vit-
ro TF-induced thrombin generation in a concentration-
dependent manner and that pooled normal IgG had no
effect on thrombin generation in the same system. These
controls confirmed that changes to thrombin genera-
tion were due to interference of TFPI activity by a com-
ponent of the IgG fractions.
The effect of IgG fractions from normal controls on
thrombin generation demonstrated a narrow inter-quar-
tile range of 97-102%. This variation may be accounted
for by the incidental presence of aPL in the IgG frac-
tions of apparently healthy subjects25 and might there-
fore influence thrombin generation. The effect of IgG
fractions from aPS subjects, however, was more variable,
with a wider inter-quartile range (89.5% - 105.5%) and
low and high values of 49% and 131%, respectively,
indicating a variety of influences from IgG fractions on
TF-induced thrombin generation. In particular, increased
thrombin generation may be due to interference with
TFPI activity, for example by anti-TFPI antibodies and/or
other cross-reacting aPL, reflecting increased hyperco-
agulability and thrombotic risk.
Anti-TFPI activity in aPS subjects was weakly corre-
lated with the effect of IgG fractions on TF-induced in
vitro thrombin generation (ρ = 0.356). Interestingly,
increased thrombin generation (above the 75% per-
centile of the normal cohort; 102%) and anti-TFPI activ-
ity were reported in 5 of the 23 aPS subjects tested. The
presence of anti-TFPI activity in the plasma of these sub-
jects could contribute significantly to an increased
thrombotic risk. A larger cohort of subjects may demon-
strate a significant positive correlation between anti-
TFPI activity and the resulting influence of IgG fractions
(or purified anti-TFPI autoantibodies from these sub-
jects) on TF-induced in vitro thrombin generation.
Low TF-induced thrombin generation (below the 25th
percentile of the normal cohort; 97%) was reported in
10 of the 23 subjects tested. This is probably due to the
presence of LA, which paradoxically interfere with in vit-
ro phospholipid-dependent coagulation tests [including
the thrombin generation assay used in this study]13 by
prolonging clotting times, thus reflecting decreased,
rather than increased thrombin generation. Each of the
10 subjects tested was positive for LA. It is also inter-
esting to note that the 5 IgG fractions that generated
increased TF-induced thrombin generation were also
positive for LA, indicating that the overall strength of
anti-TFPI activity was greater than the influence of LA.
The model used in this study therefore accounts for the
overall capacity of anti-TFPI activity in IgG fractions,
which potentially contain LA, aCL and other entities, to
influence thrombin generation, rather than the influ-
ence of anti-TFPI antibodies alone. 
This study has confirmed the presence of anti-TFPI
activity in aPS subjects, demonstrating that IgG frac-
tions generate variable influences on TF-induced throm-
bin generation and associated anti-TFPI activity with
increased thrombin generation. Whether the anti-TFPI
activity demonstrated in this in vitro system represents
the presence of in vivo anti-TFPI autoantibodies, other
aPL that interfere with TFPI activity such as anti-β2GPI26
or a combination of both, is yet to be determined. The
overall contribution of these factors and others, such as
the influence of aPL on TF expression or secretion, may
be significant in altering the balance of the TF pathway
and the development of the clinical manifestations asso-
ciated with aPS.
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